Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P.

Sci Transl Med. 2012 Jan 4;4(115):115ra1. doi: 10.1126/scitranslmed.3003155.

2.

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.

Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E.

Sci Transl Med. 2014 Nov 5;6(261):261ra153. doi: 10.1126/scitranslmed.3009185.

3.

Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.

Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, Christensen JP.

J Immunol. 2011 Feb 15;186(4):2355-64. doi: 10.4049/jimmunol.1001877. Epub 2011 Jan 21.

4.

Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.

Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, Verhoye L, Rychlowska M, Rappuoli R, Ulmer JB, Colloca S, Nicosia A, Cortese R, Leroux-Roels G, Balfe P, Bienkowska-Szewczyk K, Meuleman P, McKeating JA, Folgori A.

J Virol. 2014 May;88(10):5502-10. doi: 10.1128/JVI.03574-13. Epub 2014 Mar 5.

5.

A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.

Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, Ruggeri L, Davies ME, Tafi R, Santini C, Luzzago A, Fu TM, Bett A, Colloca S, Cortese R, Nicosia A, Folgori A.

J Virol. 2006 Feb;80(4):1688-99.

6.

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.

Kelly C, Swadling L, Capone S, Brown A, Richardson R, Halliday J, von Delft A, Oo Y, Mutimer D, Kurioka A, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Di Marco S, Siani L, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E.

Hepatology. 2016 May;63(5):1455-70. doi: 10.1002/hep.28294. Epub 2016 Jan 22.

7.

Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes.

Filskov J, Mikkelsen M, Hansen PR, Christensen JP, Thomsen AR, Andersen P, Bukh J, Agger EM.

J Virol. 2017 Jun 26;91(14). pii: e00130-17. doi: 10.1128/JVI.00130-17. Print 2017 Jul 15.

PMID:
28446674
8.

Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes.

Guan J, Wen B, Deng Y, Zhang K, Chen H, Wu X, Ruan L, Tan W.

Virol J. 2011 Nov 4;8:506. doi: 10.1186/1743-422X-8-506.

9.

A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

Fournillier A, Frelin L, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström F, Broderick KE, Sardesai NY, Bonnefoy JY, Inchauspé G, Sällberg M.

J Infect Dis. 2013 Sep;208(6):1008-19. doi: 10.1093/infdis/jit267. Epub 2013 Jun 17.

10.

Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine.

Latimer B, Toporovski R, Yan J, Pankhong P, Morrow MP, Khan AS, Sardesai NY, Welles SL, Jacobson JM, Weiner DB, Kutzler MA.

Hum Vaccin Immunother. 2014;10(8):2357-65. doi: 10.4161/hv.29590.

11.
12.

Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: A novel VLP prime-adenovirus boost strategy.

Kumar A, Das S, Mullick R, Lahiri P, Tatineni R, Goswami D, Bhat P, Torresi J, Gowans EJ, Karande AA, Das S.

Vaccine. 2016 Feb 17;34(8):1115-25. doi: 10.1016/j.vaccine.2015.11.061. Epub 2015 Dec 15.

PMID:
26700891
13.

Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.

Singh S, Vedi S, Li W, Samrat SK, Kumar R, Agrawal B.

Vaccine. 2014 May 13;32(23):2712-21. doi: 10.1016/j.vaccine.2014.02.080. Epub 2014 Mar 12.

PMID:
24631092
14.

Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting.

Rollier C, Verschoor EJ, Paranhos-Baccala G, Drexhage JA, Verstrepen BE, Berland JL, Himoudi N, Barnfield C, Liljestrom P, Lasarte JJ, Ruiz J, Inchauspe G, Heeney JL.

J Infect Dis. 2005 Sep 1;192(5):920-9. Epub 2005 Aug 1.

PMID:
16088843
15.

Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice.

Guan J, Deng Y, Chen H, Yin X, Yang Y, Tan W.

Arch Virol. 2015 Oct;160(10):2517-24. doi: 10.1007/s00705-015-2535-7. Epub 2015 Jul 28.

PMID:
26215441
16.

T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation.

Zubkova I, Choi YH, Chang E, Pirollo K, Uren T, Watanabe H, Wells F, Kachko A, Krawczynski K, Major ME.

Vaccine. 2009 Apr 28;27(19):2594-602. doi: 10.1016/j.vaccine.2009.02.045. Epub 2009 Feb 24.

PMID:
19428866
17.

Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes.

Fattori E, Zampaglione I, Arcuri M, Meola A, Ercole BB, Cirillo A, Folgori A, Bett A, Cappelletti M, Sporeno E, Cortese R, Nicosia A, Colloca S.

Gene Ther. 2006 Jul;13(14):1088-96. Epub 2006 Mar 23.

PMID:
16554842
19.

Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.

Echeverria I, Pereboev A, Silva L, Zabaleta A, Riezu-Boj JI, Bes M, Cubero M, Borras-Cuesta F, Lasarte JJ, Esteban JI, Prieto J, Sarobe P.

Hepatology. 2011 Jul;54(1):28-37. doi: 10.1002/hep.24325. Epub 2011 May 14.

PMID:
21452282
20.

Signatures of protective memory immune responses during hepatitis C virus reinfection.

Abdel-Hakeem MS, Bédard N, Murphy D, Bruneau J, Shoukry NH.

Gastroenterology. 2014 Oct;147(4):870-881.e8. doi: 10.1053/j.gastro.2014.07.005. Epub 2014 Jul 16.

Supplemental Content

Support Center